While reporting financial results for the third quarter on Thursday, healthcare company Haemonetics Corp. (HAE) narrowed its adjusted earnings guidance range for the full-year 2025, while trimming revenue and organic revenue growth outlook.
For fiscal 2025, the company now projects adjusted earnings in a range of $4.50 to $4.70 per share on total revenue growth of 3 to 5 percent, with organic revenue growth of 0 to 3 percent.
Previously, the company expected adjusted earnings in a range of $4.45 to $4.75 per share on total revenue growth of 5 to 8 percent, with organic revenue growth of 1 to 4 percent.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.